US Bancorp
PRLD icon

US Bancorp’s Prelude Therapeutics PRLD Stock Holding History

US Bancorp’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-606
Closed -$4K – 4189
2022
Q1 		$4K Buy
606
+424
+233% +$3.88K ﹤0.01% 3687
2021
Q4 		$2K Buy
182
+24
+15% +$390 ﹤0.01% 3912
2021
Q3 		$5K Buy
+158
New +$5.12K ﹤0.01% 3655
2021
Q1 		– Sell
-18
Closed -$1K – 3947
2020
Q4 		$1K Buy
+18
New +$895 ﹤0.01% 3693

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

US Bancorp's PRLD Position: Q2 2022 in Review

US Bancorp sold out of Prelude Therapeutics (PRLD) in Q2 2022, closing a stake of 606 shares — an estimated $4K sold.

US Bancorp first reported a position in PRLD in Q4 2020 and held it in 4 quarters. The position peaked at $5K in Q3 2021. 62 funds tracked by Wall St. Rank hold PRLD as of Q2 2022.

  • US Bancorp reported no remaining Prelude Therapeutics position as of Q2 2022 after selling out during the quarter.
  • US Bancorp sold 606 Prelude Therapeutics shares in Q2 2022, an estimated $4K.
  • US Bancorp first reported a position in Prelude Therapeutics in Q4 2020 and held it in 4 quarters.
  • US Bancorp's Prelude Therapeutics position peaked at $5K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2022.

Based on US Bancorp's 13F filing for Q2 2022, filed 1 Aug 2022.